Login / Signup

Underestimation of airway luminal eosinophilia by quantitative sputum cytometry.

Melanie KjarsgaardAdil AdatiaAnurag BhallaNicola LaVigneKatherine RadfordChynna HuangManali MukherjeeParameswaran Nair
Published in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2021)
Using a large sputum cytometry clinical database (17,693 viable cell counts), we demonstrate that a single time point intact cell count underestimates the prevalence of eosinophilia in a variety of airway diseases. The prevalence of eosinophilia increases from 35.6 to 60% (40% underestimation) at the 1.2% threshold, and from 26.3 to 48.5% (45% underestimation) at the 2.3% clinically relevant threshold, when free granules and a second examination are considered. This has important implications to identify the eosinophilic and Th2 high endotype both for clinical trials of anti-eosinophil therapies, and to select patients who may respond well to glucocorticosteroids and anti-IL5 therapies.
Keyphrases
  • single cell
  • clinical trial
  • cystic fibrosis
  • mycobacterium tuberculosis
  • risk factors
  • cell therapy
  • pulmonary tuberculosis
  • bone marrow
  • mesenchymal stem cells